Jeremy Abbott, DDS
Orofacial Pain · Rockville, MDNPI 1891857074
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,200 of the $1,947 with a category attached, or 61.6%. Biohaven Pharmaceuticals, Inc. accounts for 62.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,216 and has fallen 88.7% since, to $137 in 2025.
Across 14 payments — averaging $139.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Inspire Medical Systems, Inc.$352
- Mylan Specialty L.p.$119
- Harmony Biosciences LLC$119
- Idorsia Pharmaceuticals US Inc$80
- Somnomed Inc.$47
- plus $15 from 1 others
What the payments were for
- Consulting fees$1,20062%
- Food & beverage$74738%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 5 | $1,216 |
| Inspire Medical Systems, Inc. | 4 | $352 |
| Mylan Specialty L.p. | 1 | $119 |
| Harmony Biosciences LLC | 1 | $119 |
| Idorsia Pharmaceuticals US Inc | 1 | $80 |
| Somnomed Inc. | 1 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- Inspire$121
- Wakix$119
- Inspire Upper Airway Stimulation System$117
How this compares
Too few orofacial pain providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 24 | $425 |
| Gabapentin | 19 | $361 |
| Nortriptyline Hcl | 13 | $62 |
Paid to pharmacies, not to this prescriber.
Other orofacial pain in Rockville
- Marcela Romero ReyesBaltimore$13K
- Vanessa BenaventClarksville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.